Dejgaard TF, Schmidt S, Frandsen CS et al (2020) Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: the Lira Pump triala randomized, double-blinded, placebo-controlled trial
doi: 10.3390/nu13030856 90 HouYGuDPengJJiangKLiZShiJet al
Common side effects (GLP-1 medications) Nausea Vomiting Diarrhea or constipation Reduced appetite to the point of under-eating Rare but serious risks may include: Pancreatitis Gallbladder issues Growth hormone-related peptides Potential risks: Fluid retention Joint pain Insulin resistance (if misused) Long-term unknowns For newer or research peptides, long-term data is limited
100% sn xut ti Php, tun th tiu chun GMP v ISO 22000, s dng cng ngh tin tin v cao cp nh bc liposome hot cht, cng ngh Activ Anti-Rides t ph trong chm sc da v chng lo ha Mi sn phm ca Biocyte u t chng nhn DGCCRF (French Food Grade Safety Regulations) v c cc bc s v vin thm m kim nh v khuyn dng
doi: 10.1016/s0306-9877(02)00336-5
Frequency: Can be used once or twice daily, depending on your skins needs and tolerance
